Persephone Biosciences Secures $15M Seed Round to Transform Engineered Cell Therapeutics for Healthier Human Ecosystems

Persephone Biosciences is thrilled to announce a successful funding round, having raised $15,000,000 to accelerate its groundbreaking mission in the realm of synthetic biology. Founded in the summer of 2017 by pioneers Stephanie Culler, PhD, and Steve Van Dien, PhD, the company is dedicated to revolutionizing patient and infant health through engineered microbial products. By leveraging advanced synthetic and metabolic engineering techniques, Persephone is constructing an innovative end-to-end platform that industrializes the development of engineered cells capable of restoring health to damaged human ecosystems. This infusion of capital marks a significant milestone for the company, allowing it to expand research and development efforts and scale proprietary technologies towards overcoming some of the most challenging health-related issues of our time. The investment will be directed towards enhancing laboratory facilities, optimizing production processes, and expanding the talented team of experts who are committed to refining the complex interplay between microbial systems and human health. Persephone Biosciences envisions a future where engineered cells not only offer new therapeutic avenues but also provide a resilient foundation for preventive care. As the company propels forward in its quest to redefine healthcare using synthetic biology, the recent funding will catalyze a series of strategic initiatives intended to bring safe, effective, and scalable solutions to the market. This achievement reaffirms the belief of the investment community in the transformative potential of cutting-edge science to address unmet medical needs, and it underscores Persephone Biosciences’ commitment to pioneering innovative strategies that prioritize the well-being of patients and infants alike.